key: cord-0009187-p9uezojv
authors: Zimmer, Mitchell J.; Dales, Samuel
title: In vivo and in vitro models of demyelinating diseases XXIV. The infectious process in cyclosporin A treated Wistar Lewis rats inoculated with JHM virus()
date: 2004-04-15
journal: Microb Pathog
DOI: 10.1016/0882-4010(89)90003-x
sha: 7286c913fa26a50cf613a00e8de9e36b522217c8
doc_id: 9187
cord_uid: p9uezojv

In the present study we investigated age related effects of inoculum size and cellular immunity on the CNS disease caused by JHM virus (JHMV) in Wistar Lewis (WL) rats. Onset of resistance normally becomes evident by the 10th day when inoculation is made with 10(6) pfu or less. The resistance could be abrogated in 15 day old animals by increasing the dose two-fold, but with rare exceptions, in 35 day old rats an 80-fold increase in pfu fails to surmount resistance. However, treatment with the immunosuppressant drug cyclosporin A (CsA) abolished resistance, whereby rats challenged at 35 days of age were susceptible to JHMV. The histopathological evidence and disease symptoms in the CsA treated group resembled closely those observed in our previous study with athymic, nude rats. Microscopic examination of the CNS from untreated, infected rats revealed extensive inflammatory responses characterized by perivascular cuffing and mononuclear infiltrates into the neuropile. The parallel CsA treated group showed that inflammatory responses of this type in the CNS were either minimal or absent. From the present evidence, we conclude that JHMV infection, which involves both neuronal and oligodendrocytic elements, is kept in check by the cellular immune system. When cellular immunity is suppressed or absent the disease process is altered from one in which white matter demyelination predominates to another form of disease in which neuronal involvement is prominent.

Inoculation of inbred rats with defined quantities of coronavirus JHM (JHMV) elicits different types of neurological disease, depending on the age when the virus is inoculated intracerebrally (i .c .) . Infection initiated during the first few days of life results in a rapidly fatal, acute encephalomyelitis during which extensive destruction of the grey matter occurs . When older pre-weanling rats are challenged, a delayed, chronic disease frequently develops, which is characterized by progressive paralysis and presence of extensive lesions in the white matter .` In Wistar Lewis (WL) as well as several outbred rat strains tested by us, animals become resistant to JHMV by about 34 the 10th day of life, whereas Wistar Furth (WF) rats remain susceptible to the virus until weaning, about 21 days after birth ."' We hypothesized that these age-related differences between the WL and WF strains may be connected with dissimilar growth rates and maturation of the CNS .' -8 This idea is supported by in vitro studies which demonstrated that a relationship exists between oligodendrocyte differentiation/ maturation and resistance to infection by JHMV . 9`0 Another factor controlling neurological disease induced in rats by JHMV is cellular immunity . Rats either immunosuppressed with cyclosporin A (CsA) or genetically athymic remain susceptible to the infection beyond the normal age of resistance, even well past weaning . 4 To further clarify the role of JHMV and the cellular immune system, in this study we examined the influence of inoculum size, age and CsA immunosuppression on the disease process .

Relationship between inoculum size and age-related susceptibility to JHMV In several of our previous articles, we reported that WL rats fail to develop disease when inoculated i .c . with 5X10 4 pfu of JHMV by the 10th day after birth .2,3.1' This finding was confirmed in the present study . Table 1 Influence of age, size of the inoculum and immunosuppression by cyclosporin A on neurological disease in Wistar Lewis rats Groups 1 and 2 were inoculated with 10 5 pfu JHMV; group 3 with 2 x 10 5 pfu ; group 4 with 8x 105 pfu . In groups 1 a, 2a, 3a and 4a rats were not treated with CsA . Group 1 b received daily CsA injections commencing on the 9th day until the 13th day, when treatment was suspended, then resumed on the 24th day postpartum .

Group 2b received daily CsA injections commencing on the 15th day until they were suppressed on the 25th day and resumed on the 36th day postpartum .

Group 2c were injected daily with CsA commencing on the 26th day, which was 10 days post JHMV inoculation .

Group 3b received daily CsA injections commencing on 14th day of age . Group 4b received daily CsA injections commencing on 33rd day until they were suspended on the 37th day and resumed on the 48th day postpartum .

Group 4c received CsA daily, commencing on the 49th day which was 14 days post JHMV inoculation . Group 4d were injected daily with CsA, starting on the 33rd day until 37th day postpartum . In this group CsA treatment was not resumed . To examine whether resistance prior to and after weaning can be overcome by increasing the virus dose, we challenged one group of 16 day old animals (group 2a in Table 1 ) with 105 pfu, another at 15 days of age (group 3a) with 2x10' pfu and a third 35 day old group (4a) with 8x 105 pfu . It is evident from the data in Table 1 that only one of the eight rats in group 2a developed neurological symptoms whereas five of the seven rats in group 3a, receiving five times more virus at about the same age as 2a, became diseased . Among 4a animals challenged with 8x105 pfu JHMV when 35 days old, only one out of 11 developed a late onset, progressive, paralytic disease of the type described by us previously . 2 It is apparent from these data that at 15 days of age inoculation i .c . of about five to 10 times more virus than the standard dose of 5x10' pfu may be sufficient to overcome resistance . However, by 35 days, 80 times greater JHMV inocula very occasionally surmounted resistance of WL rats .

Effect of cyclosporin A on age-related resistance to neurological disease caused by JHMV Our investigation of athymic (rnu/rnu) rats showed that i .c . inoculation of JHMV, even when delayed until the 63rd-70th day of life, frequently resulted in neurological disease including paralysis .' Data from the present study revealed that CsA treatment abrogated the normal age-related resistance to JHMV of rats challenged on the tenth, 16th and 35th day of age (Table 1) . However, to be effective the drug had to be administered 2 days ahead of the virus inoculation and continually thereafter, as with rats in group 2b of Table 1 . When initiation of CsA treatment was delayed until 10th day after injection of virus, as in group 2c, or until the 14th day, as in group 4c, or when treatment around the time of inoculation was terminated and not resumed, as in group 4d, no disease developed presumably because resistance was maintained . Evidently, CsA promoted the maintenance and replication of JHMV in the CNS . Table 2 Relationship between immunosuppression with CsA and time elapsing before virus activation in the CNS of Wistar Lewis rats 'All rats were inoculated i .c . at 35 days of age with 8x 10 5 pfu . 'On the 33rd day postpartum daily injections of CsA were commenced, terminated on the 37th day and resumed on the 48th day, then continued until the time of sacrifice .

This single untreated animal developed chronic paralytic disease symptoms, as in Sorensen et al.'

Controls pfu/g brain Symptoms Treated with CSA' pfu/g brain Cyclosporin A treatment and activation of JHMV in the CNS An association between CsA treatment and manifestation of disease symptoms in post-weanling WL rats led us to carry out a systematic testing for presence of infectious virus . As shown in Table 2 , all tested rats manifesting disease symptoms contained high titers of JHMV in their brains . In one case the quantity exceeded 3x10 6 pfu/g . With age-related controls untreated with CsA, the virus was detected in a single rat out of the group of 11 tested . In this animal, in which spontaneous activation had occurred, the titer was 3 .7x10' pfu/g brain, which is over 2 log 10 less than the pfu found in an age-related CsA treated littermate (Table 2) .

Efficient clearing and eclipse of JHMV in less than one day after i .c . inoculation was evident from the assays carried out on brains of CsA-treated and control rats ( Table 2 ) . This unambiguous result showed that the input virus did not contribute to JHMV titers detected on the 18th day post-inoculation and beyond . The combined data in Tables 1 and 2 indicate that the effects of CsA have to be in place around the time of virus inoculation and continually thereafter (group 2b of Table 1 ) or must be present within 10 days after the initial treatment (group 4b of Table 1 ), if a reactivable latent type JHMV infection is to be established and maintained .

Effects of JHMV infection and cyclosporin A on histopathology in the CNS When WL rats older than ten days are inoculated i .c . with 5x104 -105 pfu of JHMV, neurological disease symptoms are very rarely manifested . 3 In the present study we examined histological sections prepared from various CNS regions of rats inoculated on the 10th day . Among group 1 a animals of Table 1 , there was no evidence of any tissue necrosis . However, prominent inflammatory responses were clearly present . Fig . 1 (c) ] . Very similar inflammatory responses were found in the CNS of CsA untreated rats in group 2a, infected on the 16th day and in group 4a rats infected on the 35th day, as illustrated in Figs 2(a) and (b) . By contrast, multiple lesions were present in the CNS of CsA-treated litter mates in groups 2b and 4b but in these animals the signs of inflammation were absent or much less prominent [ Fig . 2(c) ] . Presence of lesions could be correlated with disease symptoms as well as high virus titers (data in Table 2 ) . The disease process associated with CsA was manifested rapidly, initially as lethargy or ataxia on the first day and hind leg paresis on the second day . These rats, unless sacrificed in time, invariably died within 48-72 h after appearance of the early symptoms . This rapidly developing disease should be contrasted with the prolonged, chronic, progressive paralysis associated with JHMV infection of untreated animals .

Tissue necrosis in groups 2b and 4b was principally in grey matter tissue of the diencephalon and the mesencephalon [ Fig . 3(a) ] . In the spinal cord and rhombencephalon, including the cerebellum, both grey and white matter necrotic foci were found frequently . A rarely observed feature of histopathology among CsA treated rats of group 4b were massive mononuclear cell infiltrates at the meninges . One example in the diencephalon region close to the cerebellum is illustrated in Fig . 3(b) . 

To determine whether inflammatory responses and CNS necrotic lesions observed after JHMV infection in WL rats were similar to those found during experimental allergic encephalomyelitis (EAE), an autoimmune disease induced by neural antigen(s), we immunized 4-5 week old animals with homogenates of guinea pig spinal cord (GPSC) according to the experimental protocol of Feurer et al ." All nine WL rats receiving GPSC developed chronic-relapsing EAE exactly as described by Feurer et al." Within 10 days of injection of antigen into the hind foot pads . Among the initial symptoms were loss of tail tonicity which gradually became more severe, progressing to a hind leg paresis . Within the next week, these animals recovered but then suffered a relapse within the next two weeks . Histological sections of the spinal cord and cerebellum of animals sacrificed when displaying hind leg paresis revealed extensive perivascular cuffing in the spinal cord [ Fig . 4(a) ] and a considerable infiltration in the cerebellar tissue .

For comparison, six age-matched WF rats, which manifest only low grade inflammatory processes after JHMV infection,' when injected with GPSC, as above, failed to develop any symptoms of EAE . However, within four days of injection some edema and inflammation were observed on the hind feet among this WF group, but, these symptoms disappeared permanently during the subsequent three days . Sections of the CNS surveyed for histopathology failed to reveal tissue destruction or evidence of inflammation [compare Figs 4(a) and (b)] . From these observations we conclude that WF rats are not susceptible to the type of EAE provoked by neural antigens in WL rats .

Aspects of neurological disease of rats induced by JHMV which were considered in the present study are (a) resistance to i .c . infection during postnatal development, and (b) the role of cellular immunity and possible relationship to the hosts' genetic endowment . In WL rats the resistance to JHMV, if limited to an inoculum of 5x10 4-10 5 pfu, sets in by the 10th day of age,' but can be surmounted with increasing quantities of virus . As a consequence, even when 35 day old rats are challenged, they occasionally succumb to a late onset, chronic paralytic disease in which demyelination of the white matter predominates .' This finding implies that after weaning, when CNS myelination is completed in the rat there is a lower probability of JHMV infecting susceptible oligodendrocyte targets for which this virus has a specific tropism .'

Treatment of WL rats with CsA at concentrations known to suppress cellular immunity, 13.14 effectively abrogates the age-related resistance to JHMV, even in 35 day old animals . However, the ensuing disease process is different from that in the untreated controls but is virtually identical to one observed in post weanling athymic, rnu/rnu rats studied by us previously ." Among both the nude and CsA treated groups there is only a brief interval of two or three days between appearance of symptoms, onset of paralysis, manifestation of convulsions and death . CNS histopathology of these immunodeficient rats reveals that neuronal infection predominates being most prominent in the hippocampal and rhombocephalic areas where multiple lesions are encountered . The histopathology may explain why the course of the disease is so rapid . Occurrence of necrotic lesions, albeit small, in the white matter, indicates that oligodendrocytes and perhaps other non-neuronal cell types may also be affected . Another striking but rarely encountered similarity between CsA-treated and nude rats is an accumulation at the meninges of massive quantities of mononuclear cells as shown in Sorensen et al.,' and Fig . 2(b) here .

The different forms of CNS disease which develop in normal versus immunodeficient rats are undoubtedly connected with cellular rather than humoral immunity, because intrathecal production of anti-JHMV immunoglobulin does not appear to influence the progress of the chronic disease in euthymic rats ." Spread of infection to neurons may occur readily in CsA treated rats because a reservoir of JHMV is maintained at specific sites of grey matter in the brain, as revealed by in situ probing ." Presumably, when cellular immunity is lacking the spread of virus from the repository sites cannot be interrupted and the infection becomes disseminated . The rather limited involvement of the white matter in the disease of older CsA treated rats is perhaps due to the paucity of susceptible oligodendrocyte targets, since this cell type becomes refractory to infection by JHMV after the age-related differentiation has occurred ."

In this study, we were able to demonstrate a correlation between replication of JHMV in the CNS and manifestation of disease . Among the rats infected at 35 days of age, one control animal which developed a late-onset paralysis and virtually all those treated with CsA contained virus in the brain (Table 2) . Undoubtedly, this was progeny virus because the infectiousness of the inoculum is rapidly eclipsed to undetectable levels . However, the infectious potential of the inoculum has to be maintained in the brain for the virus to become subsequently triggered into productive replication, which occurs very often in immunosuppressed rats and rather infrequently in untreated animals . From studies with normal WF rats, there is evidence that latency with JHMV occasionally can be very prolonged, whereby virus expression in the CNS is detectable beyond 138 days after i .c . inoculation ." The initial period of a few days around the time of inoculation must be critical for establishing the latent virus reservoir because immunosuppression with CsA has to be in effect during this decisive interval .

Furthermore, to perpetuate the infection CsA treatment must be maintained or resumed, within 10 days, suggesting that in pre-weanling WL rats cellular immunity can effectively keep in check and perhaps entirely eliminate the infection .

Evidence of others that JH MV induces the proliferation of T cells recognizing myelin antigen(s), specifically MBP and that such T cells can be used to adoptively transfer EAE, 16-18 provided Preparations of CNS samples for histopathology . After removal of the CNS from control rats or those manifesting disease symptoms, the tissue was divided sagitally into equal halves . One half was homogenized and employed for estimation of virus titer by assay for plaque forming units (pfu) . The other half was fixed in 10% buffered formaldehyde, at neutral pH, dehydrated, embedded, sectioned and stained with hematoxylin and eosin, as described previously .'

Virus inoculation and assays . JHMV was propagated on L-2 cells and quantitated by plaque assay as previously described ." The pfu of the inoculum injected i .c . was varied, depending on the experimental group involved . As described in the legend of Table 1 , rats in groups 1 and 2 received 10 5 pfu at 10 and 16 days of age, respectively . Those in group 3 were injected at 15 days of age with 2 x 105 pfu . Rats in group 4 received 8 x 105 pfu at 35 days of age . Titers of JHMV in the CNS were obtained by plaque assay on L-2 cell monolayers by means of a dilution series of 10% brain homogenates as in Sorensen et al .' The fate of the infectious inoculum, in the brain was determined at 1, 3 and 5 days post-inoculation .

Immunosuppression with cyclosporin A . Cyclosporin A (CsA), obtained from Sandimmune (Sandoz Canada Inc .), was injected intraperitoneally (i .p.) to deliver 25 mg/kg/day, according to the schedule shown in Table 1 .

Chronic-relapsing experimental allergic encephalomyelitis (CREAE) . To induce the chronic relapsing type of EAE, as described by Feurer et al.," spinal cords from guinea pigs (GPSC) were isolated from 500-800g animals, homogenized and prepared as an emulsion for inoculation . The GPSC antigen in emulsified complete Freund's adjuvant with BCG cell walls added, was injected into the hind foot pads of 8 week old WL and WF rats . Assessment of EAE was according to criteria of Feurer et al ."

We are grateful to Andrea Hanington for maintenance of the animal colony and Ole Sorensen for suggestions and discussions .

Ter Meulen V . Coronavirus induced subacute demyelinating encephalomyelitis in rats : A morphological analysis

In vivo and in vitro models of demyelinating disease . III . JHM virus infection of rats

In vivo and in vitro models of demyelinating disease : endogenous factors influencing demyelinating disease caused by mouse hepatitis virus in rats and mice

In vivo and in vitro models of demyelinating disease . XVII . The infectious process in athymic rats inoculated with JHM virus

In vivo and in vitro models of demyelinating diseases-VIII : Genetic immunologic and cellular influences on JHM virus infection of rats

In vivo and in vitro models of demyelinating disease . XXI : Relationship between differentiation of rat oligodendrocytes and control of JHMV replication

Schwann cell galactocerebrodide is induced by derivatives of adenosine 3' :5'-cyclic monosphosphate

Astrocytes ependymal cells and oligodendrocytes develop on schedule in dissociated cell cultures of embryonic rat brain

In vivo and in vitro models of demyelinating disease . XI : Tropism and differentiation regulate the infectious process of coronavirus in primary explants of the rat CNS

In viva and in vitro models of demyelinating disease: activation of the adenylate cyclase system influences JHM Virus expression in explanted rat oligodendrocytes

In vivo and in vitro models of demyelinating disease-IX : progression of JHM Virus infection in the central nervous system of the rat during overt and asymptomatic phases

Chronic relapsing experimental allergic encephalomyelitis in the Lewis rat

Immunosuppression by cyclosporin A of experimental allergic encephalomyelitis

The effect of cyclosporin A in animal models of tissue transplantation

In vivo and in vitro models of demyelinating disease : JHM Virus in the rat central nervous system localized by in situ cDNA hybridization and immunofluorescent microscopy

Adoptive transfer of EAE-like lesions from rats with coronavirusinduced demyelinating encephalomyelitis

Comparative analysis of coronavirus JHM-induced demyelinating encephalomyelitis in Lewis and Brown Norway rats

Ter Meulen V. Virological and immunological aspects of coronavirus induced subacute demyelinating encephalomyelitis in rats

Allergic encephalomyelitis in the reputedly resistant Brown Norway strain of rats